5alpha-雄甾-1-烯-3beta,17beta-二醇 | 5323-27-3

• 物质功能分类: 天然产物 - 甾体化合物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 5alpha-雄甾-1-烯-3beta,17beta-二醇
• 中文别名: 1-雄烯二醇；5α-雄甾-1-烯-3beta,17beta-二醇
• 英文名称: 5α-androst-1-ene-3β,17β-diol
• 英文别名: 1-androstenediol；(3R,5S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17-diol
• CAS: 5323-27-3
• 化学式: C₁₉H₃₀O₂
• 分子量: 290.446
• InChiKey: RZFGPAMUAXASRE-YSZCXEEOSA-N

物化性质

• 熔点：
  154-156 °C
• 沸点：
  418.0±38.0 °C(Predicted)
• 密度：
  1.111

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2α-bromodihydrotestosterone 在 甲醇 、 sodium tetrahydroborate 、 Jones reagent 、 cerium(III) chloride heptahydrate 、 lithium carbonate 、 lithium bromide 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 1.33h， 生成 5alpha-雄甾-1-烯-3beta,17beta-二醇
  参考文献：
  名称：

  5α-androst-1-ene-3β,17β-二醇的新型立体选择性合成

  摘要：

  详细阐述了合成代谢类固醇及其代谢物的参考化合物5α-androst-1-ene-3β,17β-二醇的高效立体选择性合成方法。合成的关键在于使用硼氢化钠-氯化铈(III)体系作为还原剂。

  DOI：

  10.1007/s11172-023-4078-5

文献信息

• FLUORESCENCE BASED DETECTION OF SUBSTANCES
  申请人：Russell David

  公开号：US20090230322A1

  公开（公告）日：2009-09-17

  A method for the fluorescent detection of a substance, the method comprising providing particles comprising a metal or a metal oxide core, wherein one or more optionally fluorescently tagged antibodies or human specific peptide nucleic acid (PNA) oligomers for binding to a substance is/are bound, directly or indirectly, to the surface of the metal or metal oxide; contacting a substrate, which may or may not have the substance on its surface, with the particles for a time sufficient to allow the antibody/PNA oligomer to bind with the substance; removing those particles which have not bound to the substrate; if the antibodies or PNA oligomers are not fluorescently tagged, contacting the substrate with one or more fluorophores that selectively bind with the antibody and/or substance, then optionally washing the substrate to remove unbound fluorophores; and illuminating the substrate with appropriate radiation to show the fluorophores on the substrate.

  一种用于荧光检测物质的方法，该方法包括提供含有金属或金属氧化核的颗粒，其中一种或多种可选择性地荧光标记的抗体或人特异性肽核酸（PNA）寡聚体，用于结合到物质上，直接或间接地结合到金属或金属氧化物的表面；将可能在其表面具有或不具有该物质的基质与这些颗粒接触一段时间，以充分允许抗体/PNA寡聚体与该物质结合；移除那些未与基质结合的颗粒；如果抗体或PNA寡聚体未被荧光标记，则将基质与一种或多种能特异性结合抗体和/或物质的荧光剂接触，然后可选择地清洗基质以去除未结合的荧光剂；并用适当的辐射照射基质以显示基质上的荧光剂。
• Sample depletion and enrichment to improve the quality of diagnostic test results
  申请人：Veravas, Inc.

  公开号：US10948484B2

  公开（公告）日：2021-03-16

  Magnetic and non-magnetic microparticle binding surfaces for the simple, cost-effective and automatable depletion of sample interferences within the assay blocking threshold and enrichment of biomarkers are provided, as are methods and compositions for their preparation and use. The binding surfaces may comprise non-magnetic, magnetic, paramagnetic, and superparamagnetic microparticles, or combinations thereof. The methods include methods for making microparticulate binding surfaces that consist of binders, binding partners, capture moieties, or combinations thereof for multi-functional sample depletion and enrichment. Specific examples employing antibodies or fragments thereof are provided, as well as strepavidin-coated microparticles and microparticles coupled with capture moieties such as immunoglobulins. Other examples couple ligands, enzymes, and proteins, or other biologicals, polymers and chemicals commonly used in the diagnostic test formulation or design. Further provided are binding surfaces consisting of a plurality of microparticles and methods for making them. Use of the methods and compositions in connection with the depletion and enrichment of a wide variety of interferences and biomarkers is provided, particularly for use in primary blood collection tubes, secondary transfer tubes and challenging sample types such as urine, saliva and stool.

  本研究提供了磁性和非磁性微粒子结合表面，可简单、经济、自动地去除检测阻断阈值内的样品干扰并富集生物标记物，同时还提供了制备和使用这些表面的方法和组合物。结合表面可包括非磁性、磁性、顺磁性和超顺磁性微颗粒或其组合。这些方法包括制作微颗粒结合表面的方法，这些结合表面由粘合剂、结合伙伴、捕获分子或其组合组成，用于多功能样品去污和富集。提供了采用抗体或其片段的具体实例，以及链霉亲和素涂层微颗粒和与免疫球蛋白等捕获分子耦合的微颗粒。其他例子还包括配体、酶和蛋白质，或诊断检测配方或设计中常用的其他生物、聚合物和化学品。此外，还提供了由多个微颗粒组成的结合表面及其制造方法。这些方法和组合物可用于去除和富集多种干扰物和生物标记物，尤其适用于初级采血管、二次转移管以及尿液、唾液和粪便等具有挑战性的样本类型。
• Bioavailable prodrugs of androgenic steroids and related method
  申请人：——

  公开号：US20020183532A1

  公开（公告）日：2002-12-05

  A compound for supplementing the concentration of a parent androgen in a subject in vivo, wherein the parent androgen has a skeletal structure including a 17 position and the parent androgen further has a 17&bgr;-hydroxy group comprising a 17&bgr;-hydroxy hydrogen appended to the 17 position. The compound comprises a substrate having the skeletal structure of the parent androgen including a 17 position corresponding to the 17 position of the parent androgen, and a promoiety comprising an alkoxymethyl ether appended to the 17 position of the substrate as a substitute for the 17&bgr;-hydroxy hydrogen. Related compounds and methods also are disclosed.

  一种用于补充体内受试者体内母体雄激素浓度的化合物，其中母体雄激素具有包括17位的骨架结构，母体雄激素进一步具有17&bgr;-羟基，该17&bgr;-羟基包括附加到17位的17&bgr;-羟基氢。该化合物包括具有母体雄激素骨架结构的底物，该底物包括与母体雄激素的 17 位相对应的 17 位，以及原基，该原基包括附着于底物 17 位的烷氧基甲基醚，作为 17&bgr;-hydroxy 氢的替代物。还公开了相关的化合物和方法。
• Composition and method for increasing in vivo androgen concentration
  申请人：——

  公开号：US20030134828A1

  公开（公告）日：2003-07-17

  A composition is provided including a first prohormone for increasing the concentration of a Class I parent androgen in a subject in vivo, and a second prohormone for increasing the concentration of a Class II parent androgen in the subject in vivo. The first prohormone includes a first carbon-carbon double bond at the 1 position, and a first 17&bgr;-hydroxy oxygen appended to the 17 position. The first prohormone further includes a first 17-position promoiety is appended to the first 17&bgr;-hydroxy oxygen as a substitute for the 17&bgr;-hydroxy hydrogen of the Class I parent androgen. The second prohormone includes a second carbon-carbon double bond at the 4 position and a second 17&bgr;-hydroxy oxygen appended to the 17 position. The second prohormone also includes a second 17-position promoiety appended to the second 17&bgr;-hydroxy oxygen as a substitute for the 17&bgr;-hydroxy hydrogen of the Class II parent androgen.

  提供了一种组合物，其中包括用于增加体内受试者体内第一类母体雄激素浓度的第一种原激素，以及用于增加体内受试者体内第二类母体雄激素浓度的第二种原激素。第一种原激素包括位于 1 位的第一碳碳双键，以及附加到 17 位的第一 17&bgr;-羟基氧。第一种原激素还包括与第一17&bgr;-羟基氧相连的第一17位原基，作为第一类母雄激素的17&bgr;-羟基氢的替代物。第二种原激素包括位于 4 位的第二个碳碳双键和附加到 17 位的第二个 17&bgr;-羟基氧。第二种原激素还包括与第二17&bgr;-羟基氧相连的第二17位原基，作为第二类母雄激素的17&bgr;-羟基氢的替代物。
• Pharmaceutical compositions and treatment methods - 8
  申请人：Ahlem Nathaniel Clarence

  公开号：US20050159366A1

  公开（公告）日：2005-07-21

  The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

  本发明提供了由式 1 类固醇（如 16α-溴-3β-羟基-5α-雄甾烷-17-酮半水合物）和一种或多种赋形剂组成的组合物，其中组合物通常包含小于约 3% 的水。这些组合物可用于制造改良药物制剂。本发明还提供了类固醇化合物（如 16α-溴-3β-羟基-5α-雄甾烷-17-酮的类似物）的间歇给药方法和用于此类给药方案的组合物。本发明进一步提供了使用某些类固醇和类固醇类似物抑制病原体（病毒）复制、改善与免疫失调相关的症状和调节受试者免疫反应的组合物和方法。本发明还提供了制造和使用这些免疫调节组合物和制剂的方法。